BANK VONTOBEL/CALL/BIONTECH ADR/140/0.1/17.01.25 Share Price

Warrant

DE000VU962K0

Market Closed - Deutsche Boerse AG 11:20:33 22/05/2024 pm IST
0.28 EUR +133.33% Intraday chart for BANK VONTOBEL/CALL/BIONTECH ADR/140/0.1/17.01.25
Current month-11.11%
1 month-10.45%
Date Price Change
22/24/22 0.28 +133.33%
21/24/21 0.12 -6.98%
20/24/20 0.129 -2.27%
17/24/17 0.132 -7.04%
16/24/16 0.142 +5.19%

Delayed Quote Deutsche Boerse AG

Last update May 22, 2024 at 11:20 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
WKN VU962K
ISINDE000VU962K0
Date issued 19/07/2023
Strike 140 $
Maturity 17/01/2025 (240 Days)
Parity 10 : 1
Emission price 1.21
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.31
Lowest since issue 0.113
Spread 0.01
Spread %2.56%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
94.41 EUR
Average target price
105.4 EUR
Spread / Average Target
+11.62%
Consensus